Cholangiocarcinoma

Oncology
6
Pipeline Programs
8
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 6 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Taiho Oncology
Taiho OncologyNJ - Princeton
2 programs
1
1
Trifluridine/TipiracilPhase 21 trial
FutibatinibPhase 1/2Small Molecule1 trial
Active Trials
NCT02052778CompletedEst. Oct 2024
NCT04076761TerminatedEst. Sep 2022
Bristol Myers Squibb
1 program
1
BMS-936558Phase 21 trial
Active Trials
NCT04648319Terminated1Est. Jan 2022
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
DurvalumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06441747Recruiting40Est. Aug 2028
E
EisaiChina - Liaoning
1 program
1
E7090Phase 21 trial
Active Trials
NCT04238715Completed63Est. Nov 2025
EpicentRx
EpicentRxCA - La Jolla
1 program
1
RRx-001Phase 21 trial
Active Trials
NCT02452970TerminatedEst. May 2016
Alliance Pharmaceuticals
1 program
eCHEC programN/A1 trial
Active Trials
NCT05321992Recruiting480Est. Apr 2026
Mauna Kea Technologies
1 program
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct StrictureN/A1 trial
Active Trials
NCT01392274CompletedEst. Sep 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstraZenecaDurvalumab
Bristol Myers SquibbBMS-936558
EisaiE7090
Taiho OncologyTrifluridine/Tipiracil
EpicentRxRRx-001
Taiho OncologyFutibatinib
Alliance PharmaceuticalseCHEC program
Mauna Kea TechnologiespCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

Clinical Trials (8)

Total enrollment: 584 patients across 8 trials

NCT06441747AstraZenecaDurvalumab

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Start: Sep 2024Est. completion: Aug 202840 patients
Phase 2Recruiting
NCT04648319Bristol Myers SquibbBMS-936558

A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma

Start: Apr 2021Est. completion: Jan 20221 patients
Phase 2Terminated
NCT04238715EisaiE7090

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Start: Jan 2020Est. completion: Nov 202563 patients
Phase 2Completed
NCT04076761Taiho OncologyTrifluridine/Tipiracil

Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma

Start: Dec 2019Est. completion: Sep 2022
Phase 2Terminated
NCT02452970EpicentRxRRx-001

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Start: Jul 2015Est. completion: May 2016
Phase 2Terminated
NCT02052778Taiho OncologyFutibatinib

A Study of TAS-120 in Patients With Advanced Solid Tumors

Start: Jul 2014Est. completion: Oct 2024
Phase 1/2Completed
NCT05321992Alliance PharmaceuticalseCHEC program

Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand

Start: Jun 2024Est. completion: Apr 2026480 patients
N/ARecruiting
NCT01392274Mauna Kea TechnologiespCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

Start: Apr 2012Est. completion: Sep 2013
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 584 patients
8 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)